Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC-Reference-Cited by-同舟云学术

Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

Published:2024-03 Issue:3 Volume:5 Page:100638
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Vansteenkiste Johan F.^ORCID,Naidoo Jarushka,Faivre-Finn Corinne,Özgüroğlu Mustafa,Villegas Augusto,Daniel Davey,Murakami Shuji,Hui Rina,Lee Ki Hyeong,Cho Byoung Chul,Kubota Kaoru,Broadhurst Helen,Wadsworth Catherine,Newton Michael,Thiyagarajah Piruntha,Antonia Scott J.

Funder

NIHR Maudsley Biomedical Research Centre

AstraZeneca

Publisher

Elsevier BV

Reference47 articles.

1. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Postmus;Ann Oncol,2017

2. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

3. PROCLAIM: a randomized, phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced non-squamous non-small cell lung cancer;Senan;J Clin Oncol,2016

4. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;N Eng J Med,2017

5. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC;Antonia;N Eng J Med,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer;Scientific Reports;2024-08-23